MCID: ERY017
MIFTS: 49

Erythema Elevatum Diutinum malady

Categories: Rare diseases, Skin diseases, Cardiovascular diseases, Bone diseases

Aliases & Classifications for Erythema Elevatum Diutinum

Aliases & Descriptions for Erythema Elevatum Diutinum:

Name: Erythema Elevatum Diutinum 12 50 56 42 14 69

Characteristics:

Orphanet epidemiological data:

56
erythema elevatum diutinum
Age of onset: All ages; Age of death: normal life expectancy;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060567
ICD10 33 L95.1
MeSH 42 C535509
Orphanet 56 ORPHA90000
ICD10 via Orphanet 34 L95.1
MESH via Orphanet 43 C535509
UMLS via Orphanet 70 C0263398
UMLS 69 C0263398

Summaries for Erythema Elevatum Diutinum

NIH Rare Diseases : 50 erythema elevatum diutinum is a rare type of chronic cutaneous vasculitis characterized by red, purple, brown or yellow papules, plaques (thick, red patches of skin), or nodules.these lesions are located mainly on the knees, elbows, hands, feet, face, genitals and buttocks. although it is a chronic condition, most cases respond well to treatment with dapsone. the cause of this condition remains unknown.  last updated: 4/13/2010

MalaCards based summary : Erythema Elevatum Diutinum is related to vasculitis and arthritis, and has symptoms including arthralgia, myalgia and abnormal blistering of the skin. An important gene associated with Erythema Elevatum Diutinum is CXCL8 (C-X-C Motif Chemokine Ligand 8), and among its related pathways/superpathways are Innate Immune System and Cell adhesion molecules (CAMs). The drugs Heparin and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and neutrophil, and related phenotypes are cellular and hematopoietic system

Disease Ontology : 12 A vasculitis characterised by red, purple, brown or yellow papules (raised spot), plaques, or nodules, found on the backs of the hands, other extensor surfaces overlying joints, and on the buttocks.

Wikipedia : 71 Erythema elevatum diutinum is a form of... more...

Related Diseases for Erythema Elevatum Diutinum

Diseases related to Erythema Elevatum Diutinum via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
id Related Disease Score Top Affiliating Genes
1 vasculitis 10.4
2 arthritis 10.3
3 rheumatoid arthritis 10.3
4 fallopian tube carcinoma 10.3 CD79A CXCL8
5 plantar wart 10.3 CD79A CXCL8
6 keratitis 10.2
7 alcoholic neuropathy 10.2 CD40LG CD79A
8 camptodactyly vertebral fusion 10.2 CD40LG CD79A
9 spinal polio 10.2 CD40LG CD79A
10 rabies 10.2 CD40LG CD79A
11 unilateral retinoblastoma 10.2 CD40LG CD79A
12 delta chain disease 10.2 CD40LG CD79A
13 discitis 10.2 CD40LG CD79A
14 spinal canal and spinal cord meningioma 10.2 CD40LG CD79A
15 trichostrongyloidiasis 10.2 CD40LG CD79A
16 colloid adenoma 10.2 CD40LG CD79A
17 heart septal defect 10.2 CD40LG CD79A
18 cutaneous polyarteritis nodosa 10.2 CD40LG CD79A
19 mild pre-eclampsia 10.2 CD40LG CD79A
20 retinal microaneurysm 10.2 CD40LG CD79A
21 pediatric meningioma 10.2 CD40LG CD79A
22 tonsil cancer 10.2 CD40LG CD79A
23 indomethacin antenatal infection 10.2 CD40LG CD79A
24 postcricoid region cancer 10.2 CD40LG CD79A
25 acute kidney tubular necrosis 10.2 CD40LG CD79A
26 atheroembolism of kidney 10.2 CD40LG CD79A
27 partial sensory epilepsy 10.2 CD40LG CD79A
28 diabetic angiopathy 10.2 CD40LG CD79A
29 endocarditis 10.2 CD40LG CD79A
30 muscular dystrophy 10.2 CD40LG CD79A
31 dumping syndrome 10.2 CD40LG CD79A
32 striatonigral degeneration 10.2 CD40LG CD79A
33 ciliary body spindle cell melanoma 10.2 CD40LG CD79A
34 purulent endophthalmitis 10.2 CD40LG CD79A
35 mu chain disease 10.2 CD40LG CD79A
36 generalized atherosclerosis 10.2 CD40LG CD79A
37 bursitis 10.2 CD40LG CD79A
38 syphilis 10.2 CD40LG CD79A
39 homocystinuria 10.2 CD40LG CD79A
40 mental retardation, autosomal dominant 19 10.2 CD40LG CD79A
41 hemangioma of orbit 10.2 CD40LG CD79A
42 leiomyosarcoma 10.2 CD40LG CD79A
43 immunoglobulin beta deficiency 10.2 CD40LG CD79A
44 gestational diabetes 10.2 CD40LG CD79A
45 odontogenic myxoma 10.2 CD40LG CD79A
46 chronic mucocutaneous candidiasis 10.2 CD40LG CD79A
47 primary thrombocytopenia 10.2 CD40LG CD79A
48 alkhurma hemorrhagic fever 10.2 CD40LG CD79A
49 pedophilia 10.2 CD40LG CD79A
50 polyneuropathy due to drug 10.2 CD40LG CD79A

Graphical network of the top 20 diseases related to Erythema Elevatum Diutinum:



Diseases related to Erythema Elevatum Diutinum

Symptoms & Phenotypes for Erythema Elevatum Diutinum

Human phenotypes related to Erythema Elevatum Diutinum:

56 32 (show all 8)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 56 32 Very frequent (99-80%) HP:0002829
2 myalgia 56 32 Occasional (29-5%) HP:0003326
3 abnormal blistering of the skin 56 32 Frequent (79-30%) HP:0008066
4 skin rash 56 32 Very frequent (99-80%) HP:0000988
5 skin vesicle 56 32 Frequent (79-30%) HP:0200037
6 increased antibody level in blood 56 32 Frequent (79-30%) HP:0010702
7 skin nodule 56 32 Occasional (29-5%) HP:0200036
8 vasculitis in the skin 56 32 Very frequent (99-80%) HP:0200029

MGI Mouse Phenotypes related to Erythema Elevatum Diutinum:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.8 CD34 CD40LG CD79A GATA3 PECAM1 S100A9
2 hematopoietic system MP:0005397 9.76 CD34 CD40LG CD79A F13A1 GATA3 PECAM1
3 homeostasis/metabolism MP:0005376 9.56 CD40LG CD79A F13A1 GATA3 PECAM1 S100A9
4 immune system MP:0005387 9.17 CD34 CD40LG CD79A GATA3 PECAM1 S100A9

Drugs & Therapeutics for Erythema Elevatum Diutinum

Drugs for Erythema Elevatum Diutinum (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 245)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
2
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
3
Budesonide Approved Phase 4 51333-22-3 63006 5281004
4
Canagliflozin Approved Phase 4 842133-18-0
5
Insulin Aspart Approved Phase 4,Phase 3 116094-23-6 16132418
6
Insulin Glargine Approved Phase 4 160337-95-1
7
Insulin-glulisine Approved Phase 4 207748-29-6
8
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
9
Zinc Approved Phase 4,Phase 3 7440-66-6 32051 23994
10
Goserelin Approved Phase 4 65807-02-5 47725 5311128
11
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
12
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 59-30-3 6037
13
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2 58-05-9 54575, 6560146 143
14 Hormone Antagonists Phase 4,Phase 3,Phase 2
15 Hormones Phase 4,Phase 3,Phase 2
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
17 calcium heparin Phase 4,Phase 3
18 Antimetabolites Phase 4,Phase 3,Phase 2
19 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2
21 Dermatologic Agents Phase 4,Phase 3,Phase 2
22 Folic Acid Antagonists Phase 4,Phase 3,Phase 2
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
24 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
25 Vitamin B Complex Phase 4,Phase 3,Phase 2
26 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
27 Contraceptive Agents Phase 4,Phase 3
28 Adrenergic Agents Phase 4,Phase 3
29 Adrenergic Agonists Phase 4,Phase 3
30 Adrenergic beta-2 Receptor Agonists Phase 4
31 Adrenergic beta-Agonists Phase 4
32 Anti-Asthmatic Agents Phase 4,Phase 3
33 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
34 Autonomic Agents Phase 4,Phase 3,Phase 2
35 Bronchodilator Agents Phase 4,Phase 3
36 Budesonide, Formoterol Fumarate Drug Combination Phase 4
37 Formoterol Fumarate Phase 4
38 glucocorticoids Phase 4,Phase 3,Phase 2
39 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
40 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
41 Respiratory System Agents Phase 4,Phase 3
42 Hypoglycemic Agents Phase 4,Phase 3
43 Biphasic Insulins Phase 4,Phase 3
44 Coagulants Phase 4
45 insulin Phase 4,Phase 3
46 Insulin aspart, insulin aspart protamine drug combination 30:70 Phase 4,Phase 3
47 Insulin degludec, insulin aspart drug combination Phase 4,Phase 3
48 Insulin, Globin Zinc Phase 4,Phase 3
49 Insulin, Long-Acting Phase 4,Phase 3
50 Pharmaceutical Solutions Phase 4

Interventional clinical trials:

(show top 50) (show all 85)
id Name Status NCT ID Phase
1 Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With Asthma Completed NCT02062463 Phase 4
2 A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus Completed NCT01989754 Phase 4
3 Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients Completed NCT00965549 Phase 4
4 Local Phase 4 Pan-European SMART Study Completed NCT00463866 Phase 4
5 AQUACEL® Ag Dressing and Urgotul® Silver Dressing on Healing of Chronic Venous Leg Ulcers Completed NCT01084577 Phase 4
6 A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage Terminated NCT01661140 Phase 4
7 GP Extended Action Triptorelin Terminated NCT01673984 Phase 4
8 Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer Unknown status NCT00559858 Phase 3
9 Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer Unknown status NCT00392535 Phase 3
10 Dalteparin in Preventing Blood Clots in Patients With Lung Cancer Unknown status NCT00519805 Phase 3
11 Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00182715 Phase 3
12 Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation Completed NCT00412984 Phase 3
13 A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease Completed NCT00501059 Phase 3
14 A Study of Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer Completed NCT01262651 Phase 3
15 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention Completed NCT01355159 Phase 3
16 A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea Completed NCT00196794 Phase 3
17 A Study of RoActemra/Actemra (Tocilizumab) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Completed NCT02046603 Phase 3
18 Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension Completed NCT01788358 Phase 3
19 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Completed NCT01764633 Phase 3
20 A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer Completed NCT01424566 Phase 3
21 Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes Completed NCT01336023 Phase 3
22 Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease Completed NCT01313676 Phase 3
23 An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy Completed NCT00883753 Phase 3
24 An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy. Completed NCT00750880 Phase 3
25 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM Completed NCT00736099 Phase 3
26 Efficacy and Safety of Dapagliflozin in Combination With Metformin in Type 2 Diabetes Patients Completed NCT00660907 Phase 3
27 BI 1356 (Linagliptin) in Combination With Metformin and a Sulphonylurea in Type 2 Diabetes Completed NCT00602472 Phase 3
28 Respimat® Combivent Trial in Chronic Obstructive Pulmonary Disease (COPD) Completed NCT00400153 Phase 3
29 Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 Diabetes Completed NCT00184600 Phase 3
30 A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer Completed NCT00069121 Phase 3
31 Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU) Completed NCT00479661 Phase 3
32 A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain Completed NCT01439100 Phase 3
33 Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain Completed NCT01337089 Phase 3
34 A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib Completed NCT01324596 Phase 3
35 Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism Completed NCT00633893 Phase 3
36 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3
37 Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours Recruiting NCT02804815 Phase 3
38 Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease Recruiting NCT02914600 Phase 3
39 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease Recruiting NCT02914561 Phase 3
40 Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis Recruiting NCT02914535 Phase 3
41 Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis Recruiting NCT02914522 Phase 3
42 A Study to Assess the Efficacy and Safety of the Gastric-retentive AP-CD/LD in Advanced Parkinson's Patients Recruiting NCT02605434 Phase 3
43 An Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease Recruiting NCT02542696 Phase 3
44 Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD) Recruiting NCT02540954 Phase 3
45 Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 Recruiting NCT02403323 Phase 3
46 A Study of the Safety and Efficacy of Etrolizumab in Patients With Moderately to Severely Active Crohn's Disease Recruiting NCT02394028 Phase 3
47 A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02136069 Phase 3
48 Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies Recruiting NCT02118584 Phase 3
49 A Study of the Efficacy and Safety of Etrolizumab in Ulcerative Colitis Participants Who Are Refractory to or Intolerant of Tumor Necrosis Factor (TNF) Inhibitors Recruiting NCT02100696 Phase 3
50 Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis Recruiting NCT02531633 Phase 3

Search NIH Clinical Center for Erythema Elevatum Diutinum

Cochrane evidence based reviews: erythema elevatum diutinum

Genetic Tests for Erythema Elevatum Diutinum

Anatomical Context for Erythema Elevatum Diutinum

MalaCards organs/tissues related to Erythema Elevatum Diutinum:

39
Skin, Bone, Neutrophil, B Cells, Liver, Breast, Thyroid

Publications for Erythema Elevatum Diutinum

Articles related to Erythema Elevatum Diutinum:

(show top 50) (show all 183)
id Title Authors Year
1
A rare case of erythema elevatum diutinum presenting as diffuse neuropathy. ( 28050587 )
2017
2
Erythema elevatum diutinum in association with IgA monoclonal gammopathy: A rare case report. ( 27559509 )
2016
3
Chronic Localized Fibrosing Leukocytoclastic Vasculitis Associated With Lymphedema, Intralymphatic and Intravascular Lymphocytosis, and Chronic Myelogenous Leukemia: A Case Report of Unilateral Erythema Elevatum Diutinum. ( 27930381 )
2016
4
Erythema elevatum diutinum in acquired immune deficiency syndrome: Can it be an immune reconstitution inflammatory syndrome? ( 27190420 )
2016
5
Granuloma Faciale and Erythema Elevatum Diutinum in Relation to Immunoglobulin G4-Related Disease: An Appraisal of 32 Cases. ( 27124923 )
2016
6
Pediatric case of microscopic polyangiitis with skin manifestations resembling vesiculobullous type erythema elevatum diutinum with immunoglobulin A antineutrophil cytoplasmic antibody. ( 27097593 )
2016
7
Erythema elevatum diutinum coexisting with ankylosing spondylitis. ( 27708930 )
2015
8
Erythema elevatum diutinum and hypothyroidism: coincidence or causal relationship? ( 26375227 )
2015
9
A case of mistaken identity: unilateral erythema elevatum diutinum associated with IgA paraproteinaemia. ( 25754401 )
2015
10
Erythema elevatum diutinum: an atypical presentation. ( 25521326 )
2015
11
A Case of Erythema Elevatum Diutinum With Pancytopenia: Focus on Dapsone-Induced Hematologic Side Effects and Colchicine as a Safe Treatment Option. ( 26461818 )
2015
12
An atypical distribution of erythema elevatum diutinum. ( 24479627 )
2014
13
Erythema elevatum diutinum in association with dermatitis herpetiformis. ( 24616856 )
2014
14
An unusual case of Sweet syndrome in a child: overlapping presentation with erythema elevatum diutinum. ( 24521734 )
2014
15
Case of Erythema Elevatum Diutinum Associated With IgA Paraproteinemia Successfully Controlled With Thalidomide and Plasma Exchange. ( 25257541 )
2014
16
Erythema Elevatum Diutinum (EED): A Distinctive Vasculitis with Acute-on-Chronic Features. ( 24652434 )
2014
17
Erythema elevatum diutinum: a review of presentation and treatment. ( 25288365 )
2014
18
Nodular Erythema Elevatum Diutinum Mimicking Kaposi's Sarcoma in a Human Immunodeficiency Virus Infected Patient. ( 25484391 )
2014
19
An unusual case of erythema elevatum diutinum with penile and laryngeal manifestations. ( 24413401 )
2014
20
Atypical erythema elevatum diutinum or extrafacial granuloma faciale? ( 23253514 )
2013
21
Erythema elevatum diutinum. ( 23487831 )
2013
22
Erythema elevatum diutinum. ( 23442466 )
2013
23
Associated pyoderma gangrenosum, erythema elevatum diutinum, and Sweet's syndrome: the concept of neutrophilic disease. ( 24073904 )
2013
24
Erythema elevatum diutinum: a new vesiculobullous case. ( 24001509 )
2013
25
Novel use of topical dapsone 5% gel for erythema elevatum diutinum: safer and effective. ( 23652900 )
2013
26
Erythema elevatum diutinum with oral ulceration. ( 22284024 )
2012
27
Successful combination therapy with dapsone and cyclosporine for erythema elevatum diutinum with unusual appearance. ( 22132683 )
2012
28
A case of erythema elevatum diutinum associated with peripheral ulcerative keratitis. ( 22309340 )
2012
29
Alternative procedure to allow continuation of dapsone therapy despite serious adverse reaction in a case of dapsone-sensitive erythema elevatum diutinum. ( 22508198 )
2012
30
Erythema elevatum diutinum associated with peripheral ulcerative keratitis. ( 20569285 )
2011
31
Erythema elevatum diutinum in systemic lupus erythematosus. ( 20652813 )
2011
32
Progressive keratolysis with pseudopterygium associated with erythema elevatum diutinum. ( 21211842 )
2011
33
Acceleration of pulmonary interstitial fibrosis in a patient with myeloperoxidase-antineutrophil cytoplasmic antibody-positive erythema elevatum diutinum. ( 21839335 )
2011
34
Erythema elevatum diutinum: an "idiopathic" case. ( 21810392 )
2011
35
Erythema elevatum diutinum mimicking a vesiculobullous disease. ( 22126877 )
2011
36
Dapsone Hypersensitivity Syndrome That Occurred during Treatment of Pediatric Patient with Erythema Elevatum Diutinum. ( 22346260 )
2011
37
Erythema elevatum diutinum - a chronic leukocytoclastic vasculitis microscopically indistinguishable from granuloma faciale? ( 21883365 )
2011
38
Erythema elevatum diutinum associated with scleritis. ( 23130212 )
2011
39
Erythema elevatum diutinum associated with dermatomyositis. ( 21496713 )
2011
40
Is IgA antineutrophil cytoplasmic antibody a marker for patients with erythema elevatum diutinum? A further three cases demonstrating this association. ( 21143463 )
2011
41
A case of extensive erosive and bullous erythema elevatum diutinum in a patient diagnosed with human immunodeficiency virus (HIV). ( 21781074 )
2011
42
Erythema elevatum diutinum with verrucous carcinoma: a rare association. ( 20657132 )
2010
43
Successful surgical treatment of advanced erythema elevatum diutinum. ( 21358872 )
2010
44
Erythema elevatum diutinum in association with celiac disease. ( 19570095 )
2009
45
Erythema elevatum diutinum as a paraneoplastic syndrome in a patient with pulmonary lymphoepithelioma-like carcinoma. ( 18571759 )
2009
46
Erythema elevatum diutinum presenting with a giant annular pattern. ( 19261019 )
2009
47
An atypical presentation of erythema elevatum diutinum involving palms and soles. ( 19126056 )
2009
48
Erythema elevatum diutinum with unusual clinical appearance. ( 18266859 )
2008
49
Erythema elevatum diutinum with primary SjAPgren syndrome associated with IgA antineutrophil cytoplasmic antibody. ( 18547305 )
2008
50
Erythema elevatum diutinum with rare distribution as a first clinical sign of non-Hodgkin's lymphoma: a novel association? ( 18477231 )
2008

Variations for Erythema Elevatum Diutinum

Expression for Erythema Elevatum Diutinum

Search GEO for disease gene expression data for Erythema Elevatum Diutinum.

Pathways for Erythema Elevatum Diutinum

GO Terms for Erythema Elevatum Diutinum

Cellular components related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 CD34 CD40LG CD79A PECAM1

Biological processes related to Erythema Elevatum Diutinum according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of immune response GO:0050776 9.5 CD34 CD40LG TBX21
2 T cell differentiation GO:0030217 9.4 GATA3 TBX21
3 B cell proliferation GO:0042100 9.37 CD40LG CD79A
4 positive regulation of interleukin-10 production GO:0032733 9.26 CD34 CD40LG
5 positive regulation of interleukin-4 production GO:0032753 9.16 CD40LG GATA3
6 lymphocyte migration GO:0072676 8.96 GATA3 TBX21
7 glomerular endothelium development GO:0072011 8.62 CD34 PECAM1

Sources for Erythema Elevatum Diutinum

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....